The immune inhibitory receptor osteoactivin is upregulated in monocyte-derived dendritic cells by BCR-ABL tyrosine kinase inhibitors. (Q54564968)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21874302%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

title

The immune inhibitory receptor osteoactivin is upregulated in monocyte-derived dendritic cells by BCR-ABL tyrosine kinase inhibitors (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21874302%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

1 reference

Mark-Alexander Schwarzbich

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21874302%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

author name string

Michael Gutknecht

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21874302%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

Julia Salih

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21874302%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

Helmut R Salih

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21874302%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

Peter Brossart

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21874302%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

Susanne M Rittig

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21874302%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

Frank Grünebach

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21874302%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

publication date

27 August 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21874302%20AND%20SRC:MED&resulttype=core&format=json

Cancer Immunology, Immunotherapy

11 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21874302%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

volume

61

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21874302%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21874302%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

page(s)

193-202

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21874302%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s00262-011-1096-1

11 February 2020

exact match

0 references

cites work

Smart drugs: tyrosine kinase inhibitors in cancer therapy

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1096-1

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1096-1

Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1096-1

Imatinib combined with induction or consolidation chemotherapy in patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: results of the GRAAPH-2003 study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1096-1

Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1096-1

Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1096-1

Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1096-1

Dasatinib in imatinib-resistant or imatinib-intolerant chronic myeloid leukemia in blast phase after 2 years of follow-up in a phase 3 study: efficacy and tolerability of 140 milligrams once daily and 70 milligrams twice daily

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1096-1

Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1096-1

Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1096-1

Cancer immunotherapy by dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1096-1

Dendritic cells: specialized and regulated antigen processing machines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1096-1

The dendritic cell system and its role in immunogenicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1096-1

The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1096-1

Imatinib mesylate affects the development and function of dendritic cells generated from CD34+ peripheral blood progenitor cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1096-1

Effects of imatinib on monocyte-derived dendritic cells are mediated by inhibition of nuclear factor-kappaB and Akt signaling pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1096-1

BCR-ABL activity is critical for the immunogenicity of chronic myelogenous leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1096-1

Cloning and characterization of osteoactivin, a novel cDNA expressed in osteoblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1096-1

DC-HIL is a negative regulator of T lymphocyte activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1096-1

The DC-HIL/syndecan-4 pathway inhibits human allogeneic T-cell responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1096-1

Molecular cloning of a dendritic cell-associated transmembrane protein, DC-HIL, that promotes RGD-dependent adhesion of endothelial cells through recognition of heparan sulfate proteoglycans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1096-1

Post-transcriptional regulation of adapter molecules by IL-10 inhibits TLR-mediated activation of antigen-presenting cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1096-1

Quantitative real-time reverse-transcription polymerase chain reaction for diagnosis of BCR-ABL positive leukemias and molecular monitoring following allogeneic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1096-1

Target spectrum of the BCR-ABL inhibitors imatinib, nilotinib and dasatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1096-1

In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1096-1

Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1096-1

Overriding imatinib resistance with a novel ABL kinase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1096-1

A chemical and phosphoproteomic characterization of dasatinib action in lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1096-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1096-1

Exogenous siRNA mediates sequence-independent gene suppression by signaling through toll-like receptor 3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1096-1

Small interfering RNAs mediate sequence-independent gene suppression and induce immune activation by signaling through toll-like receptor 3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1096-1

Interleukin-10 receptor signaling through the JAK-STAT pathway. Requirement for two distinct receptor-derived signals for anti-inflammatory action.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1096-1

Maintained efficacy of the tyrosine kinase inhibitor imatinib mesylate in a patient with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1096-1

Tyrosine kinases as targets for the treatment of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1096-1

Masitinib in the treatment of active rheumatoid arthritis: results of a multicentre, open-label, dose-ranging, phase 2a study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1096-1

Tyrosine kinases as targets in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1096-1

Resolution of rheumatoid arthritis symptoms with imatinib mesylate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1096-1

Evolving concepts of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1096-1

10.1007/S00262-011-1096-1

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21874302%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

1 reference